Safety of Intramuscular Olanzapine in Comordibly Ill, Acutely Agitated Patients with Dementia

2.50
Hdl Handle:
http://hdl.handle.net/10755/163062
Type:
Presentation
Title:
Safety of Intramuscular Olanzapine in Comordibly Ill, Acutely Agitated Patients with Dementia
Abstract:
Safety of Intramuscular Olanzapine in Comordibly Ill, Acutely Agitated Patients with Dementia
Conference Sponsor:Emergency Nurses Association
Conference Year:2004
Author:S Yadav Marya, Rashmi
P.I. Institution Name:Eli Lilly and Company
Title:Neuroscience Medical Liaison
Contact Address:59 Lakefront, Irvine, CA, 92604, USA
Contact Telephone:(949) 262-0212
Purpose: A well-tolerated IM-administered drug may provide an important therapeutic alternative for
acutely ill patients when treatment with other formulations may not be feasible. We examined the safety of
intramuscular (IM) olanzapine (OLZ) in treating acute agitation in patients with Alzheimer's disease (AD)
or with mixed/vascular dementia (MVD) who also had critical comorbid medical conditions.
Design: Retrospective analysis of a double-blind randomized controlled clinical study.
Setting: Hospital or nursing home.
Sample: There were 272 dementia patients with major comorbid medical conditions included in this
analysis (mean age 77.6, 61% female, 40% MVD and 60% AD).
Methodology: Post-hoc analysis comparing treatment-emergent adverse events (TEAE) among patients,
who were treated for acute agitation with IM OLZ 5.0 mg, OLZ 2.5 mg, lorazepam (LZP) 1.0 mg, or placebo
(PBO) over a 24-hour period (total 1-3 injections).
Results: Prevalent baseline comorbid conditions included hypertension 40.1%,myocardial ischemia 13.6%,
stroke 6.6%, coronary artery disease 10.7%, congestive heart failure 7.4%, atrial fibrillation 6.3%, any cardiac
condition 37.1%, chronic obstructive pulmonary disease 9.9%, diabetes 10.6%, and hypothyroidism 13.6%.
Total TEAE were greater in patients treated with IM 5.0 mg OLZ than PBO in two diagnostic subgroups
(MVD, p = .023, and "any cardiac condition," p = .008).
Conclusions: In this 24-hour study, treatment of acute agitation with IM formulations of olanzapine 2.5
mg, olanzapine 5 mg, or lorazepam 1 mg were well tolerated among agitated elderly patients with dementia
and cardiac comorbidities. In patients with baseline cardiac abnormality, treatment with IM olanzapine
was not associated with incidence rates of cardiac-related or ECG-determined adverse events that were significantly
different from those observed in patients treated with placebo or IM lorazepam 1.0 mg. [Poster Presentation]
Repository Posting Date:
27-Oct-2011
Date of Publication:
17-Oct-2011
Sponsors:
Emergency Nurses Association

Full metadata record

DC FieldValue Language
dc.typePresentationen_GB
dc.titleSafety of Intramuscular Olanzapine in Comordibly Ill, Acutely Agitated Patients with Dementiaen_GB
dc.identifier.urihttp://hdl.handle.net/10755/163062-
dc.description.abstract<table><tr><td colspan="2" class="item-title">Safety of Intramuscular Olanzapine in Comordibly Ill, Acutely Agitated Patients with Dementia</td></tr><tr class="item-sponsor"><td class="label">Conference Sponsor:</td><td class="value">Emergency Nurses Association</td></tr><tr class="item-year"><td class="label">Conference Year:</td><td class="value">2004</td></tr><tr class="item-author"><td class="label">Author:</td><td class="value">S Yadav Marya, Rashmi</td></tr><tr class="item-institute"><td class="label">P.I. Institution Name:</td><td class="value">Eli Lilly and Company</td></tr><tr class="item-author-title"><td class="label">Title:</td><td class="value">Neuroscience Medical Liaison</td></tr><tr class="item-address"><td class="label">Contact Address:</td><td class="value">59 Lakefront, Irvine, CA, 92604, USA</td></tr><tr class="item-phone"><td class="label">Contact Telephone:</td><td class="value">(949) 262-0212</td></tr><tr><td colspan="2" class="item-abstract">Purpose: A well-tolerated IM-administered drug may provide an important therapeutic alternative for<br/>acutely ill patients when treatment with other formulations may not be feasible. We examined the safety of<br/>intramuscular (IM) olanzapine (OLZ) in treating acute agitation in patients with Alzheimer's disease (AD)<br/>or with mixed/vascular dementia (MVD) who also had critical comorbid medical conditions.<br/>Design: Retrospective analysis of a double-blind randomized controlled clinical study.<br/>Setting: Hospital or nursing home.<br/>Sample: There were 272 dementia patients with major comorbid medical conditions included in this<br/>analysis (mean age 77.6, 61% female, 40% MVD and 60% AD).<br/>Methodology: Post-hoc analysis comparing treatment-emergent adverse events (TEAE) among patients,<br/>who were treated for acute agitation with IM OLZ 5.0 mg, OLZ 2.5 mg, lorazepam (LZP) 1.0 mg, or placebo<br/>(PBO) over a 24-hour period (total 1-3 injections).<br/>Results: Prevalent baseline comorbid conditions included hypertension 40.1%,myocardial ischemia 13.6%,<br/>stroke 6.6%, coronary artery disease 10.7%, congestive heart failure 7.4%, atrial fibrillation 6.3%, any cardiac<br/>condition 37.1%, chronic obstructive pulmonary disease 9.9%, diabetes 10.6%, and hypothyroidism 13.6%.<br/>Total TEAE were greater in patients treated with IM 5.0 mg OLZ than PBO in two diagnostic subgroups<br/>(MVD, p = .023, and &quot;any cardiac condition,&quot; p = .008).<br/>Conclusions: In this 24-hour study, treatment of acute agitation with IM formulations of olanzapine 2.5<br/>mg, olanzapine 5 mg, or lorazepam 1 mg were well tolerated among agitated elderly patients with dementia<br/>and cardiac comorbidities. In patients with baseline cardiac abnormality, treatment with IM olanzapine<br/>was not associated with incidence rates of cardiac-related or ECG-determined adverse events that were significantly<br/>different from those observed in patients treated with placebo or IM lorazepam 1.0 mg. [Poster Presentation]</td></tr></table>en_GB
dc.date.available2011-10-27T10:38:54Z-
dc.date.issued2011-10-17en_GB
dc.date.accessioned2011-10-27T10:38:54Z-
dc.description.sponsorshipEmergency Nurses Associationen_GB
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.